Deerfield Management Company — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardRobert Jackson(Director)
Board seatJonathan Leff· per SEC Form D · $40.5M raise · filed Jan 2018
Co-investorsBiotech Investments S.R.OOUP (Osage University Partners)
BiotechIowa City, US
Steven Richard Mickelsen(Executive Officer, Director, Promoter)Raju Viswanathan(Executive Officer)David Jacques(Executive Officer)Allan Zingeler(Executive Officer, Director)
BoardDavid Booth(Director)Howard Dittrich(Director)
Board seatAndrew ElBardissi· per SEC Form D · $12M raise · filed Aug 2018
Co-investorsCadence Healthcare Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.